Influence of injection technique, drug formulation and tumor microenvironment on intratumoral immunotherapy delivery and efficacy by Patrick Hwu, Ravi Murthy, Aung Naing, Sapna P. Patel, Simon Young, Alda Tam, Nina M. Muñoz, Malea Williams, Katherine Dixon, Crystal Dupuis, Amanda McWatters, Rony Avritscher, Soraya Zorro Manrique, Kevin McHugh, David Leach, Jeffrey D. Hartgerink, Punit Prakash, Rahul A. Sheth

“…Background Intratumoral delivery of immunotherapeutics represents a compelling solution to directly address local barriers to tumor immunity. …”
Get full text

The Evolution of Radiation Therapy in Metastatic Breast Cancer: From Local Therapy to Systemic Agent by Jessica M. S. Jutzy, Jeffrey M. Lemons, Jason J. Luke, Steven J. Chmura

“…Through the release of tumor antigens, tumor DNA, and cytokines into the tumor microenvironment, radiation augments the antitumoral immune response to affect both the targeted lesion and distant sites of metastatic disease. The use of immunotherapeutics to promote antitumoral immunity has resulted in improved treatment responses in patients with metastatic disease and the combination of radiation therapy and immunotherapy has become an area of intense investigation. …”
Get full text

Humanized Mouse Models for Immuno-Oncology Research: A Review and Implications in Lung Cancer Research by Cheol-Kyu Park, MD, PhD, Maryam Khalil, BSc, Nhu-An Pham, PhD, Stephanie Wong, BSc, Dalam Ly, PhD, Adrian Sacher, MD, FRCPC, Ming-Sound Tsao, MD, FRCPC

“…Given the unmet need for improved predictive models in immuno-oncology, humanized mouse models which are co-engrafted with both human tumors and immune system components have been used to investigate novel immunotherapeutics. These models have similarly been used to predict immune-related adverse events and to develop predictive biomarkers. …”
Get full text

Role of Regulatory T Cells in Pathogenesis and Biological Therapy of Multiple Sclerosis by Milan Buc

“…In this review, we describe known mechanisms of action, efficacy, and side-effects of contemporary and emerging MS immunotherapeutical agents on Treg cells and other cells of the immune system involved in the immunopathogenesis of the disease. …”
Get full text

Virtual Screening as a Technique for PPAR Modulator Discovery by Stephanie N. Lewis, Josep Bassaganya-Riera, David R. Bevan

“…This review summarizes the high potential for obtaining further fundamental understanding of PPARγ biology and development of novel therapies for treating chronic inflammatory diseases through evolution and implementation of computational screening processes for immunotherapeutics in conjunction with experimental methods for calibration and validation of results.…”
Get full text

Immune Vulnerability of Infants to Tuberculosis by Koen Vanden Driessche, Alexander Persson, Ben J. Marais, Pamela J. Fink, Kevin B. Urdahl

“…Infant TB is a fundamentally different disease than TB in immune competent adults. Immunotherapeutics, therefore, should be specifically evaluated in infants before they are routinely employed to treat TB in this age group. …”
Get full text

Immunological Mechanisms in Allergic Diseases and Allergen Tolerance: The Role of Treg Cells by D. Calzada, S. Baos, L. Cremades-Jimeno, B. Cárdaba

“…At this respect, the role of Treg cells is one of the most promising areas of research, mainly because of their potential use as new immunotherapeutical approaches. Therefore, the aim of this review is to update the existing knowledge of the role of Tregs in this pathology deepening in their implication in allergen-specific therapy (AIT).…”
Get full text

Innate Immune Defenses in Human Tuberculosis: An Overview of the Interactions between Mycobacterium tuberculosis and Innate Immune Cells by Jonathan Kevin Sia, Maria Georgieva, Jyothi Rengarajan

“…Insights into the human innate immune response to Mtb infection are necessary for providing a rational basis for the augmentation of immune responses against Mtb infection, especially with respect to the generation of effective anti-TB immunotherapeutics and vaccines.…”
Get full text

Bevacizumab Demonstrates Prolonged Disease Stabilization in Patients with Heavily Pretreated Metastatic Renal Cell Carcinoma: A Case Series and Review of the Literature by Nicole M. Agostino, Rebecca Gingrich, Joseph J. Drabick

“…These include the immunotherapeutics, alfa-interferon, and interleukin-2, and agents that target the vascular endothelial growth factor receptor (VEGFR) via its tyrosine kinase, such as sorafenib, sunitinib, and pazopanib, or the mammalian target of rapamycin (mTOR), such as temsirolimus and everolimus. …”
Get full text

Adaptation and Molecular Characterization of Two Malaysian Very Virulent Infectious Bursal Disease Virus Isolates Adapted in BGM-70 Cell Line by Nafi’u Lawal, Mohd Hair-Bejo, Siti Suri Arshad, Abdul Rahman Omar, Aini Ideris

Get full text

New approach to generating of human monoclonal antibodies specific to the proteolytic domain of botulinum neurotoxin A by Marina Vladimirovna Silkina, Alena Sergeevna Kartseva, Alena Konstantinovna Riabko, Mariia Aleksandrovna Makarova, Metkhun Madibronovich Rogozin, Yana Olegovna Romanenko, Igor Georgievich Shemyakin, Ivan Alekseevich Dyatlov, Victoria Valerievna Firstova

“…In an effort to develop novel BoNT type A (BoNT/A) immunotherapeutics, sorted by flow cytometry plasmablasts and activated memory B cells from a donor repeatedly injected with BoNT/A for aesthetic botulinum therapy could be used due to obtain hybridomas producing native antibodies. …”
Get full text

Transient lymphocyte count decrease correlates with oncolytic adenovirus efficacy in humans: mechanistic and biomarker findings from TUNIMO phase I trial by Tuomo Alanko, Akseli Hemminki, Víctor Cervera-Carrascón, Riikka Havunen, Kristian Taipale, Dafne C A Quixabeira, Jorma Sormunen, Katriina Peltola, Suvi Sorsa, Santeri A Pakola, Elise Jirovec, Lyna Haybout, Claudia Kistler, Tatiana V Kudling, Victor Arias, James H A Clubb, Mirte van der Heijden, Teijo Pellinen, Joao M Santos

“…Background Oncolytic viruses (OVs) are promising immunotherapeutics to treat immunologically cold tumors. …”
Get full text

Knockout of the inhibitory receptor TIGIT enhances the antitumor response of ex vivo expanded NK cells and prevents fratricide with therapeutic Fc-active TIGIT antibodies by Dean A Lee, Jeremiah L Oyer, Md Faqrul Hasan, Tayler J Croom-Perez, Liza D Robles-Carrillo, Sanjana Kumar, Brendan W Andersen, Brian P Tullius, Alicja J Copik, Amanda R Campbell, Thomas A Dieffenthaller, Catherine A Cash, Jonathan E Eloriaga, Meisam Naeimi Kararoudi

“…Background Inhibitory receptor T-cell Immunoreceptor with Ig and ITIM domains (TIGIT) expressed by Natural Killer (NK) and T cells regulates cancer immunity and has been touted as the next frontier in the development of cancer immunotherapeutics. Although early results of anti-TIGIT and its combinations with antiprogrammed death-ligand 1 were highly exciting, results from an interim analysis of phase III trials are disappointing. …”
Get full text

First-in-human dose escalation trial to evaluate the clinical safety and efficacy of an anti-MAGEA1 autologous TCR-transgenic T cell therapy in relapsed and refractory solid tumors by Ignacio I Wistuba, Mamta Kalra, Linus Backert, Martin Wermke, Edwin R Parra, Jason John Luke, Apostolia M Tsimberidou, Sebastian Bunk, Mohammad B Hossain, Andrea Mayer-Mokler, Arun Satelli, Norbert Hilf, Steffen Walter, Cedrik M Britten, Van K Morris, Tobias A W Holderried, Winfried H Alsdorf, Katrin Wetzko, Borje S Andersson, Sandra Grund-Gröschke, Katrin Aslan, Anantha Marisetty, Swapna Satam, Jens Hukelmann, M Alper Kursunel, Karine Pozo, Andreas Acs, Melissa Baumeister, Claudia Wagner, Oliver Schoor, Ali S Mohamed, Delfi Krishna

Get full text